◎ Sugi Atlas

Atlas / Drug / Axitinib

Axitinib

drug
On this page

Also known as AG-013736AG-13736InlytaNSC-757441SID124950168SID144207146SID170466656AxitinibÊAxitinibÂ

Summary

Axitinib (CHEMBL1289926) is an approved small-molecule antineoplastic agent (ATC L01EK01) targeting KDR and PLK4; indicated across 51 conditions including neoplasm and renal cell carcinoma; with CIViC clinical evidence for 47 variant-indication associations (e.g. BCR::ABL1 Fusion AND ABL1 T315I in chronic myeloid leukemia).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: L01EK01
  • Targets: 2 (KDR, PLK4)
  • Indications: 51 conditions
  • Clinical trials: 175
  • Precision-oncology evidence (CIViC): 47 variant–indication associations
  • Chemistry: 386.5 Da · C22H18N4OS

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1289926
NameAxitinib
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID6450551
ChEBICHEBI:66910
ATCL01EK01
Molecular formulaC22H18N4OS
Molecular weight386.5
InChIKeyRITAVMQDGBJQJZ-FMIVXFBMSA-N

SMILES: CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)/C=C/C4=CC=CC=N4

IUPAC name: N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide

ChEBI definition: An indazole substituted at position 3 by a 2-(pyridin-2-yl)vinyl group and at position 6 by a 2-(N-methylaminocarboxy)phenylsulfanyl group. Used for the treatment of advanced renal cell carcinoma after failure of a first line systemic treatment.

Pharmacological roles (ChEBI): antineoplastic agent, tyrosine kinase inhibitor, vascular endothelial growth factor receptor antagonist.

Also known as: AG-013736, AG-13736, Axitinib, Inlyta, NSC-757441, AXITINIB, SID124950168, SID144207146, SID170466656, AxitinibÊ, axitinib, AxitinibÂ

Patent coverage: 6,544 distinct patent families (15,732 SureChEMBL compound mentions), from 4 matched compound structure(s). One matched structure accounts for 14,887 (95%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
KDRkinase insert domain receptorInhibition8.231.1%P35968
PLK4polo like kinase 4Inhibition7.3495.4% (common-essential)O00444

Broader ChEMBL bioactivity targets: 109 (assay-derived). Sample: Leucine-rich repeat serine/threonine-protein kinase 2, Hormonally up-regulated neu tumor-associated kinase, Macrophage colony-stimulating factor 1 receptor, Tyrosine-protein kinase ABL1, Protein deacetylase HDAC6, Vascular endothelial growth factor receptor 1, Mitogen-activated protein kinase kinase kinase 12, Platelet-derived growth factor receptor beta, Mast/stem cell growth factor receptor Kit, Vascular endothelial growth factor receptor 3.

Bioactivity

ChEMBL activities: 202 potent at pChembl ≥ 5 of 202 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
KDR10.7IC500.02nMCHEMBL_ACT_26137497
FLT410IC500.1nMCHEMBL_ACT_18784844
KDR10IC500.1nMCHEMBL_ACT_18784845
FLT110IC500.1nMCHEMBL_ACT_18784846
FLT110IC500.1nMCHEMBL_ACT_18854174
FLT410IC500.1nMCHEMBL_ACT_18854179
KDR9.74IC500.18nMCHEMBL_ACT_18854169
KDR9.7IC500.2nMCHEMBL_ACT_18149410
ABL19.7IC500.2nMCHEMBL_ACT_19161702
KDR9.7Ki0.2nMCHEMBL_ACT_27790658
KDR9.6IC500.25nMCHEMBL_ACT_3595752
ABL19.38IC500.42nMCHEMBL_ACT_17723420
KIT9.31Kd0.49nMCHEMBL_ACT_7587628
PDGFRA9.29Kd0.51nMCHEMBL_ACT_7589398
ABL19.26IC500.55nMCHEMBL_ACT_17723418
PDGFRB9.24Kd0.57nMCHEMBL_ACT_7587713
KDR9.15AC500.7nMCHEMBL_ACT_25167969
KDR9.04IC500.91nMCHEMBL_ACT_27142115
ABL19IC501nMCHEMBL_ACT_19161698
AURKC8.89Kd1.3nMCHEMBL_ACT_7587606
KIT8.85Kd1.4nMCHEMBL_ACT_7587629
ABL18.82Kd1.5nMCHEMBL_ACT_7589353
PDGFRB8.8IC501.6nMCHEMBL_ACT_26137498
PDGFRB8.8IC501.6nMCHEMBL_ACT_29065593
KIT8.77IC501.7nMCHEMBL_ACT_26137499
KIT8.77IC501.7nMCHEMBL_ACT_29065594
KIT8.77Kd1.7nMCHEMBL_ACT_7587627
ABL18.59IC502.6nMCHEMBL_ACT_17723419
KIT8.49Kd3.2nMCHEMBL_ACT_7587623
KIT8.46Kd3.5nMCHEMBL_ACT_7587630

Target pathways

Aggregated over 2 target gene(s): KDR, PLK4.

Top Reactome pathways

14 total, by targets touching each:

PathwayTargetsGenes
Neuropilin interactions with VEGF and VEGFR1KDR
VEGF binds to VEGFR leading to receptor dimerization1KDR
Integrin cell surface interactions1KDR
Regulation of PLK1 Activity at G2/M Transition1PLK4
Loss of Nlp from mitotic centrosomes1PLK4
Recruitment of mitotic centrosome proteins and complexes1PLK4
Loss of proteins required for interphase microtubule organization from the centrosome1PLK4
Recruitment of NuMA to mitotic centrosomes1PLK4
VEGFA-VEGFR2 Pathway1KDR
VEGFR2 mediated cell proliferation1KDR
Anchoring of the basal body to the plasma membrane1PLK4
AURKA Activation by TPX21PLK4
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB1KDR
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells1KDR

Dominant GO biological processes

GO termTargets
protein phosphorylation2
angiogenesis1
ovarian follicle development1
branching involved in blood vessel morphogenesis1
vasculogenesis1
positive regulation of protein phosphorylation1
positive regulation of endothelial cell proliferation1
lymph vessel development1
positive regulation of mesenchymal cell proliferation1
epithelial cell maturation1
endocardium development1
endothelium development1
cell surface receptor protein tyrosine kinase signaling pathway1
positive regulation of cell population proliferation1
regulation of cell shape1

Indications & clinical

Indications

51 indications (8 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
neoplasm4MONDO:0005070EFO:0000616
renal cell carcinoma4MONDO:0005086EFO:0000681
clear cell renal carcinoma4MONDO:0005005EFO:0000349
papillary renal cell carcinoma4MONDO:0017884EFO:0000640
renal carcinoma4MONDO:0005206EFO:0002890
collecting duct carcinoma4MONDO:0005220EFO:0003016
renal cell adenocarcinoma4MONDO:0005549EFO:0005708
kidney neoplasm3MONDO:0021163EFO:0003865
kidney cancer3MONDO:0002367MONDO:0002367
pancreatic ductal adenocarcinoma3MONDO:0005184MONDO:0005184
adenoid cystic carcinoma2MONDO:0004971EFO:0000231
carcinoid tumor2MONDO:0005369EFO:0004243
glioblastoma2MONDO:0018177EFO:0000519
hepatocellular carcinoma2MONDO:0007256EFO:0000182
thyroid tumor2MONDO:0015074EFO:0003841
head and neck squamous cell carcinoma2MONDO:0010150EFO:0000181
non-small cell lung carcinoma2MONDO:0005233EFO:0003060
melanoma2MONDO:0005105EFO:0000756
myelodysplastic syndrome2MONDO:0018881EFO:0000198
acute myeloid leukemia2MONDO:0018874EFO:0000222
pancreatic neoplasm2MONDO:0021040EFO:0003860
colorectal neoplasm2MONDO:0005335EFO:0004142
nasopharyngeal neoplasm2MONDO:0005375EFO:0004252
alveolar soft part sarcoma2MONDO:0011655EFO:0007143
adrenal cortex carcinoma2MONDO:0006639EFO:1000796
colorectal carcinoma2MONDO:0024331EFO:1001951
soft tissue sarcoma2MONDO:0018078EFO:1001968
prostate adenocarcinoma2MONDO:0005082EFO:0000673
biliary tract neoplasm2MONDO:0005304EFO:0003891
salivary gland cancer2MONDO:0004669MONDO:0004669
endometrium neoplasm2MONDO:0021251MONDO:0011962
solitary fibrous tumor2MONDO:0016238MONDO:0016238
skin neoplasm2MONDO:0002531EFO:0004198
gastrointestinal stromal tumor2MONDO:0011719MONDO:0011719
adrenal gland pheochromocytoma2MONDO:0004974EFO:0000239
paraganglioma2MONDO:0000448EFO:1000453
lung neoplasm2MONDO:0021117MONDO:0021117
carcinoma1MONDO:0004993EFO:0000313
malignant pleural mesothelioma1MONDO:0005112EFO:0000770
breast neoplasm1MONDO:0021100EFO:0003869
gliosarcoma1MONDO:0016681EFO:1001465
endometriosis1MONDO:0005133EFO:0001065
blast phase chronic myelogenous leukemia, BCR-ABL1 positive1MONDO:0006115EFO:1000131
gastric neoplasm1MONDO:0021085MONDO:0001056

7 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 175.

Phase distribution

PhaseTrials
PHASE298
PHASE133
Not specified17
PHASE1/PHASE216
PHASE39
PHASE2/PHASE32

Top trials by phase / activity

NCTPhaseStatusTitle
NCT05059522PHASE3ACTIVE_NOT_RECRUITINGContinued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
NCT05522231PHASE2/PHASE3ACTIVE_NOT_RECRUITINGEfficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)
NCT06364631PHASE3RECRUITINGCARE1 Pragmatic Clinical Trial
NCT07383441PHASE3NOT_YET_RECRUITINGAdding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
NCT00471146PHASE3COMPLETEDStudy Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.
NCT00678392PHASE3COMPLETEDAxitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
NCT00920816PHASE3COMPLETEDAxitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer
NCT01599754PHASE3TERMINATEDAdjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients
NCT01744249PHASE2/PHASE3COMPLETEDSandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas
NCT02684006PHASE3COMPLETEDA Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
NCT02853331PHASE3COMPLETEDStudy to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)
NCT02912572PHASE2ACTIVE_NOT_RECRUITINGAvelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
NCT02925234PHASE2RECRUITINGThe Drug Rediscovery Protocol (DRUP Trial)
NCT03092856PHASE2ACTIVE_NOT_RECRUITINGAxitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer
NCT03172754PHASE1/PHASE2ACTIVE_NOT_RECRUITINGStudy of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma
NCT03297606PHASE2RECRUITINGCanadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
NCT03595124PHASE2ACTIVE_NOT_RECRUITINGA Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)
NCT03839498PHASE2ACTIVE_NOT_RECRUITINGStudy of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma
NCT04341181PHASE2RECRUITINGProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling
NCT04996823PHASE2RECRUITINGAxitinib + Ipilimumab in Advanced Melanoma
NCT05256472PHASE2ACTIVE_NOT_RECRUITINGA Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma
NCT05327686PHASE2RECRUITINGTesting the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
NCT05363631PHASE1/PHASE2ACTIVE_NOT_RECRUITINGSeleno-L Methionine (SLM)-Axitinib-Pembrolizumab
NCT05384496PHASE2RECRUITINGAxitinib and Nivolumab for the Treatment of Mucosal Melanoma
NCT05768464PHASE2RECRUITINGPostoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors
NCT05805501PHASE2ACTIVE_NOT_RECRUITINGA Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
NCT05808608PHASE1/PHASE2ACTIVE_NOT_RECRUITINGA Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma
NCT05817903PHASE2RECRUITINGAxitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients
NCT05969496PHASE2RECRUITINGNeoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus
NCT06211114PHASE2RECRUITINGStudy to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma
NCT06279403PHASE2NOT_YET_RECRUITINGUpfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma
NCT06690697PHASE2RECRUITINGCombination of Toripalimab and JS004 Therapy for ccRCC
NCT06889649PHASE2RECRUITINGSABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC
NCT06962787PHASE2RECRUITINGA Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer
NCT07123090PHASE2RECRUITINGA Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma
NCT07159191PHASE2NOT_YET_RECRUITINGEnvafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
NCT07172386PHASE2RECRUITINGPreoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC
NCT07227415PHASE1/PHASE2RECRUITINGSymbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
NCT07469683PHASE2RECRUITINGAn Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma
NCT00071006PHASE2COMPLETEDAG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)

Clinical evidence (CIViC)

Variant × indication × effect (47 predictive associations from 57 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
BCR::ABL1 Fusion AND ABL1 T315IChronic Myeloid LeukemiaSensitivity/ResponseAxitinibCIViC CEID4369 +3
BCR::ABL1 Fusion AND ABL1 V299LChronic Myeloid LeukemiaSensitivity/ResponseAxitinibCIViC DEID4537 +1
BCR::ABL1 Fusion AND ABL1 E279KChronic Myeloid LeukemiaSensitivity/ResponseAxitinibCIViC DEID7772
BCR::ABL1 Fusion AND ABL1 F359V AND ABL1 V299LChronic Myeloid LeukemiaSensitivity/ResponseAxitinibCIViC DEID12319
BCR::ABL1 Fusion AND ABL1 M351T AND ABL1 V299LChronic Myeloid LeukemiaSensitivity/ResponseAxitinibCIViC DEID12318
BCR::ABL1 Fusion AND ABL1 T315AChronic Myeloid LeukemiaSensitivity/ResponseAxitinibCIViC DEID7768
BCR::ABL1 Fusion AND ABL1 T315I AND ABL1 F359VChronic Myeloid LeukemiaSensitivity/ResponseAxitinibCIViC DEID12316
BCR::ABL1 Fusion AND ABL1 T315I AND ABL1 H396RChronic Myeloid LeukemiaSensitivity/ResponseAxitinibCIViC DEID12317
BCR::ABL1 Fusion AND ABL1 T315I AND ABL1 M244VChronic Myeloid LeukemiaSensitivity/ResponseAxitinibCIViC DEID12315
BCR::ABL1 Fusion AND ABL1 T315LChronic Myeloid LeukemiaSensitivity/ResponseAxitinibCIViC DEID12310
BCR::ABL1 Fusion AND ABL1 T315VChronic Myeloid LeukemiaSensitivity/ResponseAxitinibCIViC DEID7766
KDR R1032QColorectal CancerSensitivity/ResponseLenvatinib + Axitinib + Cabozantinib + DovitinibCIViC DEID9339
LYN Y508FChronic Myeloid LeukemiaSensitivity/ResponseAxitinibCIViC DEID4804
BCR::ABL1 Fusion AND ABL1 E255VChronic Myeloid LeukemiaResistanceAxitinibCIViC DEID4441 +1
BCR::ABL1 Fusion AND ABL1 F317LChronic Myeloid LeukemiaResistanceAxitinibCIViC DEID4390 +1
BCR::ABL1 Fusion AND ABL1 G250EChronic Myeloid LeukemiaResistanceAxitinibCIViC DEID4320 +1
BCR::ABL1 Fusion AND ABL1 M351TChronic Myeloid LeukemiaResistanceAxitinibCIViC DEID4399 +1
BCR::ABL1 Fusion AND ABL1 Q252HChronic Myeloid LeukemiaResistanceAxitinibCIViC DEID4323 +1
BCR::ABL1 Fusion AND ABL1 Y253HChronic Myeloid LeukemiaResistanceAxitinibCIViC DEID4329 +1
BCR::ABL1 Fusion AND ABL1 D276GChronic Myeloid LeukemiaResistanceAxitinibCIViC DEID4360
BCR::ABL1 Fusion AND ABL1 E255KChronic Myeloid LeukemiaResistanceAxitinibCIViC DEID4355
BCR::ABL1 Fusion AND ABL1 E255V AND ABL1 V299LChronic Myeloid LeukemiaResistanceAxitinibCIViC DEID12314
BCR::ABL1 Fusion AND ABL1 E292LChronic Myeloid LeukemiaResistanceAxitinibCIViC DEID7773
BCR::ABL1 Fusion AND ABL1 F311IChronic Myeloid LeukemiaResistanceAxitinibCIViC DEID4477
BCR::ABL1 Fusion AND ABL1 F317L AND ABL1 F359VChronic Myeloid LeukemiaResistanceAxitinibCIViC DEID12320
BCR::ABL1 Fusion AND ABL1 F317RChronic Myeloid LeukemiaResistanceAxitinibCIViC DEID7774
BCR::ABL1 Fusion AND ABL1 F317VChronic Myeloid LeukemiaResistanceAxitinibCIViC DEID4535
BCR::ABL1 Fusion AND ABL1 F359IChronic Myeloid LeukemiaResistanceAxitinibCIViC DEID4529
BCR::ABL1 Fusion AND ABL1 F359VChronic Myeloid LeukemiaResistanceAxitinibCIViC DEID3822
BCR::ABL1 Fusion AND ABL1 F486SChronic Myeloid LeukemiaResistanceAxitinibCIViC DEID4438

+17 more predictive associations (showing top 30 by level).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 1 clinical and 19 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

178 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
CRIZOTINIBChEMBL + PubChemPhase 4 (approved)KDR, PLK4
ERLOTINIBChEMBL + PubChemPhase 4 (approved)KDR, PLK4
FEDRATINIBChEMBL + PubChemPhase 4 (approved)KDR, PLK4
GEFITINIBChEMBL + PubChemPhase 4 (approved)KDR, PLK4
IMATINIBChEMBL + PubChemPhase 4 (approved)KDR, PLK4
PAZOPANIBChEMBL + PubChemPhase 4 (approved)KDR, PLK4
REGORAFENIBChEMBL + PubChemPhase 4 (approved)KDR, PLK4
CERITINIBChEMBLPhase 4 (approved)KDR, PLK4
DASATINIBChEMBLPhase 4 (approved)KDR, PLK4
ENTRECTINIBChEMBLPhase 4 (approved)KDR, PLK4
MIDOSTAURINChEMBLPhase 4 (approved)KDR, PLK4
NINTEDANIBChEMBLPhase 4 (approved)KDR, PLK4
SORAFENIBChEMBLPhase 4 (approved)KDR, PLK4
SUNITINIBChEMBLPhase 4 (approved)KDR, PLK4
VANDETANIBChEMBLPhase 4 (approved)KDR, PLK4
ALISERTIBChEMBLPhase 3KDR, PLK4
CEDIRANIBChEMBLPhase 3KDR, PLK4
DOVITINIBChEMBLPhase 3KDR, PLK4
LESTAURTINIBChEMBLPhase 3KDR, PLK4
LINIFANIBChEMBLPhase 3KDR, PLK4
AT-9283ChEMBLPhase 2KDR, PLK4
BMS-777607ChEMBLPhase 2KDR, PLK4
CENISERTIBChEMBLPhase 2KDR, PLK4
DANUSERTIBChEMBLPhase 2KDR, PLK4
DEFOSBARASERTIBChEMBLPhase 2KDR, PLK4
ELLAGIC ACIDChEMBLPhase 2KDR, PLK4
ENMD-2076ChEMBLPhase 2KDR, PLK4
FORETINIBChEMBLPhase 2KDR, PLK4
GLESATINIBChEMBLPhase 2KDR, PLK4
ILORASERTIBChEMBLPhase 2KDR, PLK4
MERESTINIBChEMBLPhase 2KDR, PLK4
OSI-632ChEMBLPhase 2KDR, PLK4
R-406ChEMBLPhase 2KDR, PLK4
REBASTINIBChEMBLPhase 2KDR, PLK4
SU-014813ChEMBLPhase 2KDR, PLK4
TANDUTINIBChEMBLPhase 2KDR, PLK4
TOZASERTIBChEMBLPhase 2KDR, PLK4
AfatinibPubChemApprovedKDR, PLK4
BinimetinibPubChemApprovedKDR, PLK4
SelumetinibPubChemApprovedKDR, PLK4
FOSTAMATINIBChEMBL + PubChemPhase 4 (approved)PLK4
GENTIAN VIOLETChEMBL + PubChemPhase 4 (approved)KDR
ABEMACICLIBChEMBLPhase 4 (approved)KDR
ABROCITINIBChEMBLPhase 4 (approved)KDR
ACALABRUTINIBChEMBLPhase 4 (approved)KDR
ALECTINIBChEMBLPhase 4 (approved)KDR
AUROTHIOGLUCOSEChEMBLPhase 4 (approved)KDR
BRIGATINIBChEMBLPhase 4 (approved)KDR
CABOZANTINIBChEMBLPhase 4 (approved)KDR
CABOZANTINIB S-MALATEChEMBLPhase 4 (approved)KDR
DABRAFENIBChEMBLPhase 4 (approved)PLK4
ENASIDENIBChEMBLPhase 4 (approved)KDR
ERDAFITINIBChEMBLPhase 4 (approved)KDR
ESTRAMUSTINEChEMBLPhase 4 (approved)KDR
FOSTAMATINIB DISODIUMChEMBLPhase 4 (approved)KDR
FRUQUINTINIBChEMBLPhase 4 (approved)KDR
FUTIBATINIBChEMBLPhase 4 (approved)KDR
GILTERITINIBChEMBLPhase 4 (approved)PLK4
GLAFENINEChEMBLPhase 4 (approved)KDR
HEXACHLOROPHENEChEMBLPhase 4 (approved)KDR

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot